Skip to main content
Get Matched with a Provider
Medication

Venlafaxine (effexor, effexor XR)

Venlafaxine is a psychiatric medication available by prescription only. It belongs to a class of medications called serotonin-norepinephrine reuptake inhibitors (SNRIs) and is used to treat mood and anxiety disorders. The original brands were Effexor and Effexor XR. Desvenlafaxine is a chemically similar medication, and the original brand name is Pristiq.

Learn About Effexor Treatment

Connect with a psychiatric clinician—online or in person—for a comprehensive evaluation. If appropriate, they may discuss whether a treatment like venlafaxine (Effexor or Effexor XR) could be considered within your care plan.

Schedule an appointment with a Psychiatric Clinician

What Conditions Does Venlafaxine Treat?

FDA-Approved Uses:

Common Non-FDA Uses:

How Psychiatric Medication Prescription Decisions Are Made

1

Find a psychiatric clinician who meets your needs

Option 1

Search our psychiatrist directory to find a qualified provider

Provider Directory

Option 2

Locate a nearby clinic to schedule your initial appointment

Locations Directory
2

Meet 1:1 for a comprehensive psychiatric evaluation

During your first session, a psychiatric clinician will evaluate your symptoms, medical history, and treatment goals. If appropriate, they may discuss whether medication – including SNRIs like Venlafaxine (Effexor or Effexor XR) – could be considered. Treatment decisions like this will always prioritize safety, clinical best practices, and your individual needs.

3

Step 3: Begin treatment and ongoing monitoring

Once a personalized treatment plan is established, your provider will monitor your response to any prescribed medication and adjust the plan as needed. If medication is part of your care, then, if clinically appropriate, your provider may handle prescription renewals online during or after regular follow-ups as clinically appropriate in accordance with LifeStance treatment protocols.

240+ Insurances Accepted

Aetna
Anthem/Empire BCBS-Medicare, Anthem Blue Cross, Anthem/Empire BCBS, Anthem Blue Cross-Medicare, Anthem BCBS-Medicare, Anthem BCBS
Blue Cross Blue Shield (BCBS)
CareFirst BlueCross BlueShield, CareFirst BlueCross BlueShield-Medicare
Evernorth (Cigna), Evernorth (Cigna) (HealthPartners), Evernorth (Cigna)-Medicare
Highmark Blue Cross Blue Shield, Highmark Blue Shield, Highmark Blue Shield-Medicare, Highmark Blue Cross Blue Shield-Medicare
Kaiser Permanente (Southeast)-Medicare, Kaiser Permanente Washington-Medicare, Kaiser Permanente (SoCal)-Medicare, Kaiser Permanente (Southeast), Kaiser Permanente Washington, Kaiser Permanente (SoCal), Kaiser Permanente (Northwest), Kaiser Permanente (Northwest)-Medicare
Medicare
Optum, UnitedHealthcare, Optum, UnitedHealthcare-Medicare
Providence Health Plan, Providence Health Plan-Medicare
Quartz, Quartz-Medicare
Quest Behavioral Health
Regence BlueCross BlueShield, Regence BlueCross BlueShield-Medicare
View All Accepted Insurances
Struggling with Anxiety, Depression, or Pain?

Struggling with Anxiety, Depression, or Pain?

Everyone’s experience with anxiety or depression is different. A psychiatric clinician may help you find the right treatment path—whether that includes Venlafaxine (Effexor or Effexor XR) or another option that fits your needs. Discuss medication options with your treating provider.

Psychiatric Clinician Directory

FAQs About Venlafaxine (Effexor or Effexor XR)

Effexor (venlafaxine) is FDA-approved for major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. Some clinicians may also prescribe it off-label for conditions like PTSD or PMDD.

No. Effexor is an SNRI (serotonin-norepinephrine reuptake inhibitor), affecting both serotonin and norepinephrine.

Effexor is immediate-release (taken 2–3x/day). Effexor XR is extended-release (once daily) and may provide steadier levels.

Effexor (venlafaxine) may lead to weight changes, but weight gain is not known to be one of its most common side effects. Some individuals may lose weight early in treatment due to reduced appetite or nausea, while others may experience weight gain over time. The overall effect varies from person to person. Changes in appetite, metabolism, and physical activity may also influence weight while taking this medication.

Effexor (venlafaxine) may cause weight loss, especially when first starting the medication. The effect is typically temporary, and weight may fluctuate with both losses and gains reported in different individuals.

Try to avoid alcohol while on Effexor. Combining alcohol with Effexor (venlafaxine) may increase drowsiness, dizziness, and impaired judgment. Also, alcohol may diminish the effectiveness of Effexor.

A psychiatric clinician may prescribe Effexor when the benefits outweigh risks. Some studies note potential neonatal adaptation/withdrawal symptoms after birth, but this must be compared to the impact of untreated mental illness on the fetus and pregnancy. Decisions should only be made with a healthcare professional.

Venlafaxine passes into breast milk in small amounts. A clinician will weigh benefits and potential risks.

Effexor may be prescribed off-label to reduce hot flashes, including menopause-related or treatment-related hot flashes.

Many individuals often see early changes (sleep/energy/appetite) in 1–2 weeks, with fuller effects in 4–6 weeks. If the effect is insufficient after 4–6 weeks, the prescribing provider may consider a dosage increase.

Nausea, dry mouth, sweating, dizziness, insomnia, and appetite changes are common side effects of Effexor. At higher doses, blood pressure may increase.

As of publication date, the cost of brand-name Effexor XR generally ranges from about $524 to $638 for a 30-day supply, depending on the dosage strength. Generic venlafaxine extended-release is typically priced about $12 to $14 at most dosages for 30 capsules.

If you have insurance, your out-of-pocket cost will depend on your supporting diagnosis and plan type (e.g., commercial, Medicare, Medicaid) and may include a copay or coinsurance.

Effexor is known for its relatively low side effect profile for long-term use when monitored by a psychiatric clinician. Regular follow-ups are important to monitor side effects, progress, and blood pressure.

Only stop Effexor treatment if and when recommended by your psychiatric clinician. Your provider will create a taper plan to help reduce the risk of withdrawal symptoms such as dizziness, irritability, or “brain zaps” (brief electrical-like jolts in the brain).

Effexor is not FDA-approved for use in children or adolescents. Any use in pediatric populations should be directed and closely monitored by a qualified psychiatric specialist.

Always follow your psychiatric provider’s directions on when to take prescribed medications. If a dose is missed, ask your prescribing clinician for instructions. Missing doses may cause temporary uncomfortable discontinuation symptoms, but it often does not pose significant health risks for many individuals.

Both are SNRIs. Cymbalta (duloxetine) is also FDA-approved for several pain conditions (e.g., diabetic neuropathy, fibromyalgia), whereas Effexor is not.

The primary difference between Effexor (venlafaxine) and Prozac (fluoxetine) is their drug class and the neurotransmitters they affect. Effexor is a serotonin-norepinephrine reuptake inhibitor (SNRI), which increases levels of both serotonin and norepinephrine. Prozac is a selective serotonin reuptake inhibitor (SSRI), which primarily increases serotonin.

The primary difference between Effexor (venlafaxine) and Zoloft (sertraline) is their drug class and the neurotransmitters they affect. Effexor is a serotonin-norepinephrine reuptake inhibitor (SNRI), which increases levels of both serotonin and norepinephrine. Zoloft is a selective serotonin reuptake inhibitor (SSRI), which primarily increases serotonin.

Desvenlafaxine is an SNRI antidepressant and the active metabolite of venlafaxine. It works similarly to Effexor and is available as the brand-name medication Pristiq.

Pristiq (desvenlafaxine) is FDA-approved for major depressive disorder (MDD). Some clinicians may also prescribe it off-label for anxiety-related conditions, depending on the patient’s needs and response.

Pristiq (desvenlafaxine) is the active metabolite of venlafaxine. Both are SNRIs and work in similar ways. Effexor comes in both immediate-release and extended-release forms, while Pristiq is extended-release only.

Both medications affect serotonin and norepinephrine. Effexor’s effects may vary more with dose increases, while Pristiq has a more predictable dose-response curve. A psychiatric clinician will determine which option fits your specific symptoms and medical history.

Desvenlafaxine is the primary active metabolite of venlafaxine. Both are SNRIs and work in similar ways, but they come in different formulations and may have different dosing schedules or side effect profiles.

Yes. Both Pristiq (desvenlafaxine) and Effexor (venlafaxine) belong to the serotonin-norepinephrine reuptake inhibitor (SNRI) class.

Pristiq is officially only approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD) in adults. However, healthcare providers sometimes prescribe it off-label for conditions like generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder based on clinical evidence and experience. “Off-label use” means a doctor is prescribing a medication for a condition other than the one it was originally approved for. This is a common and legal practice when a healthcare provider believes the medication will be effective for a individual’s specific needs.

photo of LifeStance provider Joshua Nathan, MD

Medically Reviewed By:

Joshua Nathan, MD
View Profile
Dr. Joshua Nathan, a Board-Certified Psychiatrist, and a Distinguished Fellow of the American Psychiatric Association, sees stigma – from others and from ourselves - as the biggest challenge in mental illness treatment. He encourages people to not judge themselves on whatever problems they are facing, and he helps them feel safe to open up and allow for healing. Dr. Nathan takes joy in helping people with mental health concerns and values the trust patients place in him. Dr. Nathan treats adults struggling with mood and bipolar disorders, depression, ADHD, anxiety challenges such as panic disorder, agoraphobia, OCD, PTSD, and more. He listens to each person’s story, observes how they are faring, and shares his understanding of what is happening, so there is a basis for starting or continuing treatment. He considers medications as one tool among many for healing and recovery in mental health. During treatment, Dr. Nathan uses an eclectic framework for understanding mental illness and coping. Trained in psychoanalysis, he finds that existential understanding helps many people reduce suffering, but cognitive-behavioral techniques are more practical in helping people move forward. Thus, he typically employs a combination of theories and techniques, guided by the patient's problems, needs, and experiences. He is also an Official ADHD Evaluator for the National Football League. Dr. Nathan earned an undergraduate degree from the University of Illinois at Urbana-Champaign, a medical doctorate from the University of Illinois at Chicago, and completed postgraduate residency training at Brown University. He works with adults of all ages, but has a special fondness for working with young and middle-age adults.

References

  1. Drugs.com. (n.d.). Effexor XR prices, coupons, copay cards & patient assistance. Retrieved October 13, 2025, from https://www.drugs.com/price-guide/effexor-xr

  2. Drugs.com. (n.d.). Venlafaxine prices, coupons, copay cards & patient assistance. Retrieved October 13, 2025, from https://www.drugs.com/price-guide/venlafaxine#oral-capsule-extended-release-75-mg

  3. Holland J, Brown R. Neonatal venlafaxine discontinuation syndrome: A mini-review. Eur J Paediatr Neurol. 2017 Mar;21(2):264-268. doi: 10.1016/j.ejpn.2016.11.003. Epub 2016 Nov 25. PMID: 27931774.

  4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved November 12, 2025, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

In 2007, the FDA released a black box warning that antidepressants were correlated to the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18–24) during short-term studies of major depressive disorder (MDD) and other psychiatric conditions. Gibbons et. al (2007) also published a study that found no evidence of antidepressant treatment increasing the risk of suicide attempts among its patients (ages 18-65+). The main message is that there is an inherent relationship between depression and suicidality so close monitoring of antidepressant-treated patients (especially children, adolescents, and young adults) is always necessary. For a comprehensive overview of these medications’ uses and risks, see the U.S. Food and Drug Administration (FDA) drug label.